JP2013537237A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537237A5
JP2013537237A5 JP2013529372A JP2013529372A JP2013537237A5 JP 2013537237 A5 JP2013537237 A5 JP 2013537237A5 JP 2013529372 A JP2013529372 A JP 2013529372A JP 2013529372 A JP2013529372 A JP 2013529372A JP 2013537237 A5 JP2013537237 A5 JP 2013537237A5
Authority
JP
Japan
Prior art keywords
methyl
butyl
carbon atoms
amino
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013529372A
Other languages
English (en)
Japanese (ja)
Other versions
JP6045495B2 (ja
JP2013537237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051990 external-priority patent/WO2012037490A1/en
Publication of JP2013537237A publication Critical patent/JP2013537237A/ja
Publication of JP2013537237A5 publication Critical patent/JP2013537237A5/ja
Application granted granted Critical
Publication of JP6045495B2 publication Critical patent/JP6045495B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013529372A 2010-09-16 2011-09-16 眼圧を低下させるための[3−(1−(1h−イミダゾール−4−イル)エチル)−2−メチルフェニル]メタノールのエステル・プロドラッグ Active JP6045495B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
US61/383,370 2010-09-16
PCT/US2011/051990 WO2012037490A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure

Publications (3)

Publication Number Publication Date
JP2013537237A JP2013537237A (ja) 2013-09-30
JP2013537237A5 true JP2013537237A5 (https=) 2016-11-10
JP6045495B2 JP6045495B2 (ja) 2016-12-14

Family

ID=44675870

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013529360A Withdrawn JP2013541527A (ja) 2010-09-16 2011-09-16 網膜疾患を治療するための[3−(1−(1h−イミダゾール4−イル)エチル)−2−メチルフェニル]メタノールのエステル・プロドラッグ
JP2013529372A Active JP6045495B2 (ja) 2010-09-16 2011-09-16 眼圧を低下させるための[3−(1−(1h−イミダゾール−4−イル)エチル)−2−メチルフェニル]メタノールのエステル・プロドラッグ
JP2013529373A Active JP6073229B2 (ja) 2010-09-16 2011-09-16 [3−(1−(1h−イミダゾール−4−イル)エチル)−2−メチルフェニル]メタノールのエステル・プロドラッグ
JP2013529371A Withdrawn JP2013537236A (ja) 2010-09-16 2011-09-16 皮膚疾患及び状態を治療するための[3−(1−(1h−イミダゾール4−イル)エチル−2−メチルフェニル]メタノールのエステル・プロドラッグ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013529360A Withdrawn JP2013541527A (ja) 2010-09-16 2011-09-16 網膜疾患を治療するための[3−(1−(1h−イミダゾール4−イル)エチル)−2−メチルフェニル]メタノールのエステル・プロドラッグ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013529373A Active JP6073229B2 (ja) 2010-09-16 2011-09-16 [3−(1−(1h−イミダゾール−4−イル)エチル)−2−メチルフェニル]メタノールのエステル・プロドラッグ
JP2013529371A Withdrawn JP2013537236A (ja) 2010-09-16 2011-09-16 皮膚疾患及び状態を治療するための[3−(1−(1h−イミダゾール4−イル)エチル−2−メチルフェニル]メタノールのエステル・プロドラッグ

Country Status (28)

Country Link
US (9) US8492557B2 (https=)
EP (13) EP3050564B1 (https=)
JP (4) JP2013541527A (https=)
KR (7) KR101952457B1 (https=)
CN (5) CN103209694A (https=)
AR (4) AR083018A1 (https=)
AU (4) AU2011301932C1 (https=)
BR (4) BR112013006362A2 (https=)
CA (8) CA2812191C (https=)
CL (4) CL2013000735A1 (https=)
CY (3) CY1121024T1 (https=)
DK (9) DK2616068T3 (https=)
ES (10) ES2607084T3 (https=)
HU (5) HUE047476T2 (https=)
IL (4) IL225280A0 (https=)
MX (4) MX2013003004A (https=)
MY (4) MY161607A (https=)
NZ (1) NZ608751A (https=)
PL (7) PL3348264T3 (https=)
PT (7) PT2616069T (https=)
RU (4) RU2013116405A (https=)
SG (4) SG188571A1 (https=)
SI (5) SI3348264T1 (https=)
TR (1) TR201909249T4 (https=)
TW (4) TW201240661A (https=)
UA (1) UA112973C2 (https=)
WO (4) WO2012037453A1 (https=)
ZA (4) ZA201302193B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241553B1 (en) * 2009-02-13 2019-04-10 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
JP7584802B2 (ja) * 2018-08-24 2024-11-18 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性stingタンパク質アゴニスト
WO2022221071A1 (en) * 2021-04-16 2022-10-20 Ads Therapeutics Llc Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69307505T2 (de) 1992-05-13 1997-07-24 Sandoz-Patent-Gmbh, 79539 Loerrach Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
MXPA05012679A (es) * 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20060209374A1 (en) * 2003-07-14 2006-09-21 Koninklijke Philips Electronics N.V. Projection device
MXPA06002716A (es) * 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP4955543B2 (ja) 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
NZ553341A (en) 2004-09-24 2010-11-26 Allergan Inc 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
JP2012517433A (ja) 2009-02-06 2012-08-02 アラーガン インコーポレイテッド アルファ2bおよび/またはアルファ2cアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物
EP3241553B1 (en) * 2009-02-13 2019-04-10 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol

Similar Documents

Publication Publication Date Title
JP2013537237A5 (https=)
LTPA2020006I1 (lt) GDF gaudyklės, skirtos naudoti anemijos gydymui
AR109356A2 (es) Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona
HUE036813T2 (hu) 1,2,5-Oxadiazolok mint indolamin-2,3-dioxigenáz inhibitorok
EP2635301A4 (en) CYTOTOXIC ACTIVE SUBSTANCES WITH NEW ANSAMITOCIN DERIVATIVES
IL206789A (en) Substituted cyclic amide compound, a pharmaceutical composition comprising it and use of the compound or the pharmaceutical composition in the preparation of a medicament
BRPI0906055A2 (pt) "embalagem refechável"
DK2341905T4 (da) Depotformuleringer med ikke-vandige bærere
EP2358806A4 (en) Solvent bondable thermoplastic elastomers
EP2238752A4 (en) IMPROVEMENTS FOR ONE APPLICATION
BRPI0913806A2 (pt) "composição"
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0909577A2 (pt) "papelão de baixa densidade"
PL3320912T3 (pl) Immunoterapia na bazie 2,3-dioksygenazy indoloaminy
BRPI0914533A2 (pt) "métodos"
EP2726803A4 (en) INJECTION LACES WITH DIPPED PEAKS
EP2381954A4 (en) METHOD AND COMPOSITIONS BASED ON SHIGATOXIN TYPE 2 PROTEIN
JP2011175111A5 (https=)
EP2279532A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
BRPI0923401A2 (pt) Métodos para o preparo de aril amidas.
EP2269147A4 (en) WEBSITES TRANSLATED BY USERS AFTER PROVISION
BRPI0916363A2 (pt) derivados de 4,5-di-hidro-oxazol-2-ila
EP2679610A4 (en) POLYOXYALKYLENE MODIFIED VINYL ACETAL POLYMER AND COMPOSITION THEREWITH
EP2583171A4 (en) USER-ENHANCED REVERSE ENGINEERING
FR2968310B1 (fr) Compositions a base de 1,1,1,4,4,4-hexafluorobut-2-ene et de 3,3,4,4,4-pentafluorobut-1-ene